Moderna, Inc. — Director's Dealing 2021

Apr 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-04-12

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-12	Common Stock	M	5000	$12.21	Acquired	5000	Direct
2021-04-12	Common Stock	S	863	$137.16	Disposed	4137	Direct
2021-04-12	Common Stock	S	1400	$138.06	Disposed	2737	Direct
2021-04-12	Common Stock	S	1824	$139.38	Disposed	913	Direct
2021-04-12	Common Stock	S	413	$140.22	Disposed	500	Direct
2021-04-12	Common Stock	S	400	$141.79	Disposed	100	Direct
2021-04-12	Common Stock	S	100	$143.09	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-12	Stock Option (Right to Buy)	$12.21	M	5000	Disposed	2027-10-03	Common Stock (5000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.66 to $137.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.70 to $138.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.86 to $139.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.94 to $140.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.61 to $142.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).